Project cooperationUpdated on 20 September 2024
New vaccine platform
Knowledge Transfer & International Projects at CiQUS - Center for Research in Biological Chemistry and Molecular Materials
Santiago de Compostela, Spain
About
Subunit vaccines with intrinsic adjuvancy, overcoming drawbacks of inactivated or attenuated vaccines.
Our platform allows the production of Microspheres (400 - 4000 nm) loaded with the proteins of interest, made in any expression system (mammalian, baculovirus, bacteria).
Concept demonstrated in animal healthcare. Recombinant vaccine incorporating Bluetongue (BTV) or African Horse Sickness viruses epitopes has generated significant levels of neutralizing antibodies, protecting mice towards a lethal challenge.
-
Vaccines 2022, 10(7), 1124 https://doi.org/10.3390/vaccines10071124
-
Vaccine, 2020, 38, 882-889 https://doi.org/10.1016/j.vaccine.2019.10.087
-
Antiviral Research, 2017, 142, 55 http://dx.doi.org/10.1016/j.antiviral.2017.03.010
SARS-COV-2 vaccine project funded by European Vaccine Initiative (EVI) and Spanish funds.
Similar opportunities
Expertise
- Healthcare
Fernando Casal
Knowledge Transfer & International Projects at CiQUS - Center for Research in Biological Chemistry and Molecular Materials
Santiago de Compostela, Spain
Project cooperation
Enzyme Immobilization & Stabilization. Biomed Applications
Fernando Casal
Knowledge Transfer & International Projects at CiQUS - Center for Research in Biological Chemistry and Molecular Materials
Santiago de Compostela, Spain
Project cooperation
Participation in consortia with public funding
- Early
- Research
Dirk Weigelt
Director Processes & Innovation at RISE Research Institutes of Sweden
Södertälje, Sweden